Maurya Santosh K, Maurya Akhilesh Kumar, Mishra Nidhi, Siddique Hifzur R
Molecular Cancer Genetics & Translational Research Lab, Section of Genetics, Department of Zoology, Aligarh Muslim University, Aligarh, India.
Indian Institute of Information Technology Allahabad, Prayagraj, India.
J Recept Signal Transduct Res. 2020 Dec;40(6):605-612. doi: 10.1080/10799893.2020.1772298. Epub 2020 Jun 1.
Recently, a pathogen has been identified as a novel coronavirus (SARS-CoV-2) and found to trigger novel pneumonia (COVID-19) in human beings and some other mammals. The uncontrolled release of cytokines is seen from the primary stages of symptoms to last acute respiratory distress syndrome (ARDS). Thus, it is necessary to find out safe and effective drugs against this deadly coronavirus as soon as possible. Here, we downloaded the three-dimensional model of NSP10/NSP16 methyltransferase (PDB-ID: 6w6l) and main protease (PDB-ID: 6lu7) of COVID-19. Using these molecular models, we performed virtual screening with our anti-viral, inti-infectious, and anti-protease compounds, which are attractive therapeutics to prevent infection of the COVID-19. We found that top screened compound binds with protein molecules with good dock score with the help of hydrophobic interactions and hydrogen bonding. We observed that protease complexed with Cyclocytidine hydrochloride (anti-viral and anti-cancer), Trifluridine (anti-viral), Adonitol, and Meropenem (anti-bacterial), and Penciclovir (anti-viral) bound with a good docking score ranging from -6.8 to -5.1 (Kcal/mol). Further, NSP10/NSP16 methyltransferase complexed with Telbivudine, Oxytetracycline dihydrate (anti-viral), Methylgallate (anti-malarial), 2-deoxyglucose and Daphnetin (anti-cancer) from the docking score of -7.0 to -5.7 (Kcal/mol). In conclusion, the selected compounds may be used as a novel therapeutic agent to combat this deadly pandemic disease, SARS-CoV-2 infection, but needs further experimental research.HighlightsNSP10/NSP16 methyltransferase and main protease complex of SARS CoV-2 bind with selected drugs.NSP10/NSP16 methyltransferase and protease interacted with drugs by hydrophobic interactions.Compounds show good DG binging free energy with protein complexes.Ligands were found to follow the Lipinski rule of five.
最近,一种病原体被鉴定为新型冠状病毒(SARS-CoV-2),并被发现可在人类和其他一些哺乳动物中引发新型肺炎(COVID-19)。从症状的初始阶段到最后的急性呼吸窘迫综合征(ARDS),都可见细胞因子的失控释放。因此,有必要尽快找到针对这种致命冠状病毒的安全有效的药物。在此,我们下载了COVID-19的NSP10/NSP16甲基转移酶(PDB-ID:6w6l)和主要蛋白酶(PDB-ID:6lu7)的三维模型。利用这些分子模型,我们用我们的抗病毒、抗感染和抗蛋白酶化合物进行了虚拟筛选,这些化合物是预防COVID-19感染的有吸引力的治疗方法。我们发现,筛选出的顶级化合物通过疏水相互作用和氢键与蛋白质分子结合,具有良好的对接分数。我们观察到,蛋白酶与盐酸环胞苷(抗病毒和抗癌)、曲氟尿苷(抗病毒)、阿东糖醇、美罗培南(抗菌)和喷昔洛韦(抗病毒)复合,对接分数在-6.8至-5.1(千卡/摩尔)之间,结合良好。此外,NSP10/NSP16甲基转移酶与替比夫定、二水合土霉素(抗病毒)、没食子酸甲酯(抗疟疾)、2-脱氧葡萄糖和瑞香素(抗癌)复合,对接分数在-7.0至-5.7(千卡/摩尔)之间。总之,所选化合物可作为一种新型治疗剂来对抗这种致命的大流行疾病——SARS-CoV-2感染,但需要进一步的实验研究。
要点
SARS-CoV-2的NSP10/NSP16甲基转移酶和主要蛋白酶复合物与所选药物结合。
NSP10/NSP16甲基转移酶和蛋白酶通过疏水相互作用与药物相互作用。
化合物与蛋白质复合物显示出良好的DG结合自由能。
发现配体符合Lipinski五规则。